Williams David M, Alberts Barbara-Alex, Sharaf Asem, Sharaf Giselle, Bain Stephen C, Kalhan Atul, Min Thinzar
Diabetes Centre, Morriston Hospital, Swansea Bay University Health Board, Swansea, SA6 6NL, UK.
Diabetes Centre, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK.
Diabetes Ther. 2024 Jul;15(7):1639-1646. doi: 10.1007/s13300-024-01590-x. Epub 2024 May 9.
Oral semaglutide improves cardiovascular risk factors in people with type 2 diabetes (T2D) in clinical trials, though real-world evidence is limited. We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice.
People with T2D initiated on oral semaglutide in secondary care diabetes clinics at two hospital sites in Wales (United Kingdom) were included. Data were collected on reasons for oral semaglutide initiation and changes in bodyweight, blood pressure, glycemic control, and lipid profiles over follow-up at 3-6 months, and at 6-12 months. Data were collected to determine the safety of oral semaglutide.
Seventy-six patients were included, with a median age 59.3 [51.4-67.6] years, and 38 (50.0%) patients were female. The most common reasons for oral semaglutide were need for weight loss and improved glycemia (69.8%), and improved glycemia alone (25.0%). Oral semaglutide associated with significantly reduced bodyweight (- 3.3 kg), body mass index (BMI) (- 0.9 kg/m), glycated hemoglobin (HbA1c) (- 11 mmol/mol), and total cholesterol (- 0.4 mmol/l) by 3-6 months follow-up. At 6-12 months, there was a significant reduction in systolic blood pressure (- 7.0 mmHg), in addition to sustained reductions in other metabolic parameters. By 12 months, 18 (23.6%) patients had discontinued the drug, largely resulting from gastrointestinal disturbance, but there were no serious events in this cohort.
Oral semaglutide was effective in improving cardiovascular risk factors in this real-world population living with T2D, and no serious events were identified related to oral semaglutide in this patient group.
在临床试验中，口服司美格鲁肽可改善2型糖尿病（T2D）患者的心血管危险因素，不过真实世界证据有限。我们旨在确定口服司美格鲁肽对我们诊所常规收集的临床数据的实际影响。
纳入在英国威尔士两个医院地点的二级护理糖尿病诊所开始使用口服司美格鲁肽的T2D患者。收集了开始使用口服司美格鲁肽的原因以及随访3至6个月和6至12个月时体重、血压、血糖控制和血脂谱的变化数据。收集数据以确定口服司美格鲁肽的安全性。
纳入76例患者，中位年龄59.3[51.4 - 67.6]岁，38例（50.0%）为女性。开始使用口服司美格鲁肽的最常见原因是需要减重和改善血糖（69.8%），以及单纯改善血糖（25.0%）。随访3至6个月时，口服司美格鲁肽与体重显著降低（-3.3千克）、体重指数（BMI）（-0.9千克/米²）、糖化血红蛋白（HbA1c）（-11毫摩尔/摩尔）和总胆固醇（-0.4毫摩尔/升）相关。在6至12个月时，收缩压显著降低（-7.0毫米汞柱），此外其他代谢参数持续降低。到12个月时，18例（23.6%）患者停药，主要原因是胃肠道不适，但该队列中未发生严重事件。
口服司美格鲁肽对这一患有T2D的真实世界人群改善心血管危险因素有效，且该患者组中未发现与口服司美格鲁肽相关的严重事件。
